Filing Flows

Filing Flows › Evommune (EVMN) › Next earnings date

Evommune (EVMN) earnings on Nov 16, 2026: what to expect

Evommune (EVMN) is expected to report earnings on Nov 16, 2026 (estimated), in 8 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.83 (−$1.02 to −$0.67, 11 estimates), against −$8.07 and $10.0M a year ago. It beat the EPS estimate in 33% of the quarters on record; Filing Flows' model gives it a 58% chance of beating next time.

Report dateNov 16, 2026 (estimated)
Days to go8
EPS estimate−$0.83
Beat rate33%

The last report

Evommune reported revenue of $10.0M for the third quarter 2025, net loss $12.5M. How it makes money → · Every quarter →

Evommune: EPS against the estimate, last 3 reportsEvommune: EPS against the estimate, last 3 reportsEstimateReported−$11.36−$8.07Dec 25−$0.84−$1.43Mar 26−$0.67−$0.89Aug 26
Latest (Aug 26): Estimate −$0.67, Reported −$0.89.

Evommune's latest quarter

Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.

Questions

When does EVMN report earnings?

Evommune is expected to report on Nov 16, 2026 (estimated).

What are analysts expecting from Evommune?

EPS of −$0.83 for the quarter.

Does Evommune usually beat earnings?

It beat the consensus EPS estimate in 33% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.